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Football players who have either physical symptoms or disease after injury may need to be treated with
specific medicines that are on the list of prohibited substances. Therapeutic use exemption may be granted
to such players, in accordance with strictly defined criteria—these are presented in this article. Procedures
of how to request for an abbreviated or a standard therapeutic use exemption are explained, and data on
therapeutic use exemptions (UEFA and FIFA, 2004 and 2005) are also presented.
A
football player who has physical symptoms and signs
or acute or chronic disease following an injury may
need to be treated with a medicine that is on the list of
prohibited substances. A therapeutic use exemption (TUE)
permitting the use of such a substance or method that is on
the prohibited list, may be granted to the player, depending
to the clinical situation.
An exemption will be granted only in strict accordance
with the following criteria1:
N The player shall submit an application for TUE no less
than 21 days before participating in an event.
N The player would experience a significant impairment to
health if the prohibited substance or method were to be
withheld in the course of treating an acute or chronic
medical condition.
N The therapeutic use of the prohibited substance or method
would produce no additional enhancement of perfor-
mance other than that which might be anticipated by a
return to a state of normal health following the treatment
of a legitimate medical condition. The use of any
prohibited substance or method to increase ‘‘low-normal’’
levels of any endogenous hormone is not considered an
acceptable therapeutic intervention.
N There is no reasonable therapeutic alternative to the use of
the otherwise prohibited substance or method.
N The necessity for the otherwise prohibited substance or
method cannot be a consequence, wholly or in part, or
prior non-therapeutic use of any substance from the
prohibited list.
N The TUE will be cancelled by the granting body, if:
– The player does not promptly comply with any
requirements or conditions imposed by the FIFA
[Fédération Internationale de Football Association]
Doping Control Sub-Committee granting the exemp-
tion.
– The term for which the TUE was granted has expired.
– The player is advised that the TUE has been withdrawn
by the FIFA Doping Control Sub-Committee.
N An application for a TUE will not be considered for
retroactive approval except in cases where:
– Emergency treatment or treatment of an acute medical
condition was necessary, or
– Due to exceptional circumstances, there was insuffi-
cient time or opportunity for an applicant to submit, or
the granting body to consider, an application prior to
doping control.
N Confidentiality of information: The applicant shall provide
written consent for the transmission of all information
pertaining to the application to members of the FIFA
granting body and, as required, other independent medical
or relevant scientific experts. If the assistance of external,
independent experts is required, all details of the applica-
tion will be circulated without identifying the player
involved in the doctor’s care. The applicant shall also give
written consent to the decisions of the FIFA granting body
to be distributed to the involved medical personnel of
other relevant anti-doping organisations under the provi-
sions of the FIFA Doping Control Regulations. The
members of the granting body involved will conduct all
of their activities in strict confidence according to the
Hippocratic Oath and the medico-legal and ethical rules of
confidentiality.
FIFA proposes using the standard application forms for the TUE
applications as described in the ‘‘International Standard for
TUE’’2 (downloadable from WADA website (www.wada-ama.
org/rtecontent/document/standard.pdf and www.wada-ama.





As a result of the agreement between the World Anti-
Doping Agency (WADA) and FIFA to implement the
requirements of the WADC, in March 2004, FIFA and all
other football confederations immediately introduced a TUE
process for all national and international players participating
in the different competitions. The WADA TUE-committee is
informed about any approval and rejection and FIFA will
disclose any information to the medical staff of WADA on
request.
Abbreviations: TUE, therapeutic use exemption, WADA, World Anti-
Doping Agency; WADC, World Anti-Doping Code
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In agreement with FIFA, and according to article 4.4 of the
WADA code,3 the TUE applications procedure has been put
into operation for football players as shown in table 1. To
avoid misunderstandings, players and team doctors have
been told that a TUE request may be submitted to only one
body at a time. The same TUE request may NOT be submitted
to several different bodies. To deal with these TUE requests,
FIFA and the confederations have created, according to the
WADA International Standard, their own panels of indepen-
dent doctors, called therapeutic use exemption committees
(TUECs)). These committees review each request and the
medical evidence before granting a TUE.
WADA has designed two TUE forms—abbreviated and
standard—one of which is selected and used depending on
the treatment needed by the player (table 2).
ABBREVIATED TUE
Abbreviated TUE requests are valid as soon as FIFA, or a
confederation, or a member association’s TUEC has received
the request. Treatment may start immediately after the
receipt is confirmed. However, the TUEC has the right to ask
for additional information should the applied indication for
glucocorticosteroids or b2 agonists appear doubtful. FIFA has
also decided that for a b2 agonist TUE, following a clinical
diagnosis of exercise induced or allergic asthma the results of
lung function tests have to be submitted to substantiate the
clinical diagnosis. This decision of the FIFA Medical
Committee clearly stresses the importance of sound clinical
diagnosis following state of the art assessment to avoid
misuse of b2 agonists in the absence of clear clinical
diagnosis. In this respect FIFA endorses the May 2001
statement of the IOC (International Olympic Committee)
Medical Committee workshop on asthma and b2 agonists.
4
STANDARD TUE
In the case of a standard TUE application for which specialist
expertise is required, the TUE committee appoints external
independent experts for a second opinion to justify the
decision. Standard TUE requests are valid as soon as FIFA or
a confederation has sent the player a certificate of approval,
except in rare cases of an acute life threatening condition, for
which retroactive approval may be considered.
DATA ON USE OF CURRENT PROCEDURE
The process of application for a TUE was introduced
systematically within the FIFA member associations and
confederations after the introduction of the WADC in 2003.
FIFA receives applications for TUEs from players participat-
ing in international competitions, such as qualifying matches
for world cups (male and female and different age groups)
and for the final competition of the world cups. The Union of
European Football Associations (UEFA), on the other hand,
receives applications for confederation competitions, such as
Table 1 Procedure for therapeutic use exemption (TUE)
For TUE application to be addressed to Request made by
National players participating in domestic FIFA member association, a national Player and club
competitions only (this includes friendly anti-doping organisation, or a competent doctor
matches abroad) public authority or association
International players called up to FIFA/confederations Player and national
participate in international team team doctor
competitions and international friendly
matches
International players participating in club FIFA/confederations Player and club
competitions doctor
International players called up by member
association in FIFA competitions (that is,
2006 World Cup qualifiers) FIFA Player and national
team doctor
Table 2 Indications for abbreviated and standard
therapeutic use exemption (TUE)
Abbreviated TUE Standard TUE
Use the abbreviated TUE form only
for glucocorticosteroids administered
by non-systemic routes (locally) and for
b2 agonists (formoterol, salbutamol,
salmeterol, and terbutaline) by inhalation
Use the standard TUE form
for any treatment involving a
substance or method on the




do NOT require a TUE anymore
Granted automatically upon receipt
of the completed application by the
relevant organisation (a check by
the TUEC may be carried out at any
time during the duration of the TUE)
Will be examined by the
TUEC
Table 3 Documentation of approved
therapeutic use exemptions (TUEs): FIFA and
UEFA
Year
Abbreviated TUEs Standard TUEs
UEFA FIFA UEFA FIFA
2004 251 140 14 23
2005 299 101 20 11
What is already known
TUEs are indispensable for improving medical cover of
athletes with health impairments while avoiding anti-doping
violations. However, many physicians are still unaware of the
requirements and procedures for applying for a TUE.
What is new
The article summarises the criteria for granting a TUE,
describes the correct procedure to be followed when
requesting a TUE, and explains the differences between an
abbreviated and standard TUE request.
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Euro 2004, and international club competitions, such as the
Champions League. The total number of approved abbre-
viated and standard TUEs issued by the FIFA and UEFA in
2004 and 2005 are summarised in table 3.
The application process operates in a way that there is
mutual recognition of the approval by member associations,
the confederations, and FIFA. However, FIFA, if informed,
reviews the application and decision of the member associa-
tion, and FIFA has the right of appeal. Once a TUE has been
approved, the confidential medical information is filed at
FIFA and a copy of the approval is sent to WADA according
the WADC international standard for therapeutic use
exemption.
Authors’ affiliations
. . . . . . . . . . . . . . . . . . . . .
J Dvorak, FIFA Medical Assessment and Research Centre, and
Department of Neurology, Schulthess Clinic, Zurich, Switzerland
D Kirkendall, FIFA Medical Research and Assessment Centre, and
Department of Orthopaedics, University of North Carolina, Chapel Hill,
NC, USA
M Vouillamoz, UEFA Anti Doping Unit, Nyon, Switzerland
Competing interests: None declared
REFERENCES
1 FIFA. Doping Control Regulations. Available at www.fifa.com/documents/
fifa/regulations/dopingreglement_06_e.pdf (accessed 3 May 2006).
2 World Anti-Doping Code 2003. Available at: www.wada-ama.org/World
Anti-Doping Agency. International Standard for therapeutic use exemptions,
2005. www.wada-ama.org/rtecontent/document/international_standard.
pdf (accessed 3 May 2006).
3 World Anti-Doping Code. Available at: www.wada-ama.org/rtecontent/
document/code_v3.pdf (accessed 3 May 2006).
4 International Olympic Committee press release. Available at
www.olympic.org/uk/news/media_centre/press_release_uk.asp?id = 439
(accessed 3 May 2006).
i42 Dvorak, Kirkendall, Vouillamoz
www.bjsportmed.com
